Raymond James & Associates’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-15,281
| Closed | -$587K | – | 3979 |
|
|
2023
Q2 | $587K | Buy |
15,281
+1,404
| +10% | +$36.1K | ﹤0.01% | 2831 |
|
|
2023
Q1 | $321K | Buy |
13,877
+34
| +0.2% | +$810 | ﹤0.01% | 3193 |
|
|
2022
Q4 | $363K | Sell |
13,843
-214
| -2% | -$4.74K | ﹤0.01% | 3101 |
|
|
2022
Q3 | $276K | Buy |
14,057
+339
| +2% | +$6.8K | ﹤0.01% | 3238 |
|
|
2022
Q2 | $240K | Buy |
+13,718
| New | +$215K | ﹤0.01% | 3387 |
|
|
2020
Q4 | – | Sell |
-4,690
| Closed | -$57K | – | 3906 |
|
|
2020
Q3 | $57K | Hold |
4,690
| – | – | ﹤0.01% | 3436 |
|
|
2020
Q2 | $54K | Hold |
4,690
| – | – | ﹤0.01% | 3369 |
|
|
2020
Q1 | $64K | Hold |
4,690
| – | – | ﹤0.01% | 3286 |
|
|
2019
Q4 | $28K | Hold |
4,690
| – | – | ﹤0.01% | 3596 |
|
|
2019
Q3 | $25K | Hold |
4,690
| – | – | ﹤0.01% | 3530 |
|
|
2019
Q2 | $36K | Hold |
4,690
| – | – | ﹤0.01% | 3529 |
|
|
2019
Q1 | $93K | Hold |
4,690
| – | – | ﹤0.01% | 3402 |
|
|
2018
Q4 | $62K | Hold |
4,690
| – | – | ﹤0.01% | 3364 |
|
|
2018
Q3 | $172K | Hold |
4,690
| – | – | ﹤0.01% | 3340 |
|
|
2018
Q2 | $164K | Hold |
4,690
| – | – | ﹤0.01% | 3323 |
|
|
2018
Q1 | $218K | Sell |
4,690
-9
| -0.2% | -$329 | ﹤0.01% | 3087 |
|
|
2017
Q4 | $176K | Buy |
4,699
+9
| +0.2% | +$393 | ﹤0.01% | 3104 |
|
|
2017
Q3 | $250K | Sell |
4,690
-40
| -0.8% | -$2.38K | ﹤0.01% | 2907 |
|
|
2017
Q2 | $270K | Buy |
4,730
+40
| +0.9% | +$2.01K | ﹤0.01% | 2792 |
|
|
2017
Q1 | $252K | Hold |
4,690
| – | – | ﹤0.01% | 2804 |
|
|
2016
Q4 | $267K | Sell |
4,690
-20
| -0.4% | -$1.21K | ﹤0.01% | 2705 |
|
|
2016
Q3 | $293K | Buy |
+4,710
| New | +$333K | ﹤0.01% | 2642 |
|
Raymond James & Associates's KDNY Position: Q3 2023 in Review
Raymond James & Associates sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 15,281 shares — an estimated $587K sold.
Raymond James & Associates first reported a position in KDNY in Q3 2016 and held it in 22 quarters. The position peaked at $587K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Raymond James & Associates reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Raymond James & Associates sold 15,281 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $587K.
- Raymond James & Associates first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2016 and held it in 22 quarters.
- Raymond James & Associates's Chinook Therapeutics, Inc. Common Stock position peaked at $587K in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.